XRAY

Dentsply Sirona Inc. (XRAY) | Rumor.io

Dentsply Sirona

XRAY

Attention (50-day avg)0%

Attention rank (50-day avg)#2,513

Bullish sentiment (50-day avg)75%

Price to earnings ratio-3.09

Market capitalization1.9B

Earnings per share-2.73

Dividend yield (TTM)6.9%

Revenue (annual)3.7B

Net income (annual)-598M

Social

What share of all stock conversation is about XRAY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Feb 27

DENTSPLY SIRONA Inc. (XRAY) has seen a 10.7% rally after better-than-expected Q4 sales, with a 3.07% gap and heavy trading interest.
The company's low float has created accumulation dynamics, with institutional accumulation intensifying pressure and supply constraint against 86 GW EIA forecast tailwind demand scarcity.
Analysts maintain a bullish stance on XRAY, with Baird raising the price target from $12 to an unspecified amount, and Evercore ISI Group raising the price target from $12 to an unspecified amount.

Generated by AI

Sentiment

Of the messages about XRAY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50% -50	83.33% -3.15	86.14% -8.04
Bearish	0%	50% new	16.67% +3.15	13.86% +8.04

Bullish· Mar 1

DENTSPLY SIRONA Inc.'s (XRAY) earnings beat estimates, with a 3c beat on EPS consensus and a $44.66M beat on revenue consensus.
The company's FY19 adj. EPS guidance of $2.25-$2.40 exceeded consensus estimates of $2.17, contributing to a 15% stock price increase.
XRAY's strong earnings report led to a significant price jump, with the stock closing up 17.65% and outperforming large-cap peers.

Bearish· Apr 19

The CEO and CFO of DENTSPLY SIRONA Inc. ($XRAY) have departed within a week, raising concerns about the company's leadership.
The company has issued downside guidance, with expected EPS of $0.48-0.52 and Q1 revenue of $965 million, compared to consensus estimates of $0.67 and $1.02 billion.
Multiple analysts have downgraded their ratings on $XRAY, including Bank of America, Robert W. Baird, and William Blair, citing concerns about the company's management and earnings outlook.

Generated by AI

Topics

Of the messages about XRAY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	0%	52.82%
Analysts	—	100%	100%	7.06%
Technical Analysis	—	0%	0%	13.28%
Earnings	—	0%	0%	26.55%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0.28%

Earnings· May 10

Dentsply Sirona's Q1 earnings missed street expectations, with a non-GAAP EPS of $0.52 missing by $0.02 and revenue of $965M missing by $17.05M.
The company guided FY22 EPS below consensus and revenue below consensus, with updated guidance of $2.35-$2.55 EPS and revenue of $4.10-$4.20 billion.
Dentsply Sirona's Q1 earnings resulted in a stock price decline of 3.30% to $39.25, with the company's market value reaching $7.84B.

Analysts· Aug 8

Morgan Stanley downgraded DENTSPLY SIRONA $XRAY to "Equal Weight".
Robert W. Baird downgraded DENTSPLY SIRONA $XRAY to "Neutral".
Stifel Nicolaus cut DENTSPLY SIRONA $XRAY's price target to $46.

Announcements· Feb 28

Dentsply Sirona expects FY23 net sales of $3.85B-$3.95B, vs. $3.82B estimate, and adjusted EPS of $1.80-$2.00, vs. $1.84 estimate.
The company reported Q4 2022 results, with net sales of $1.10B and EPS of $0.55, beating estimates and guiding FY23 EPS in-line and revs above consensus.
Dentsply Sirona reported a new government contract worth $457,801.45 for its Sirona X-Ray for Dental Expansion.

Controversies· Nov 2

Dentsply Sirona completes internal investigation, but details of the investigation are not disclosed.
The investigation's outcome is not explicitly stated, leaving investors with unanswered questions.
The company's handling of the investigation has raised concerns among investors and stakeholders.

Generated by AI

Community

Of the messages about XRAY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	88.73%	62.7%
Newcomers	0%	50%	11.27%	37.3%

Regulars· Feb 28

Dentsply Sirona reported Q4 non-GAAP EPS of $0.46, beating estimates by $0.13, and revenue of $983M, beating by $43.89M.
The company guides FY23 net sales of $3.85B-$3.95B, vs. $3.82B estimate, and adjusted EPS of $1.80-$2.00, in-line with estimates.
Dentsply Sirona's FY23 organic sales growth is expected to be approximately 1%, with adjusted EBITDA margin greater than 15%, beating expectations.

Newcomers· Feb 27

DENTSPLY SIRONA (XRAY) is a global leader in dental technology and digital workflow solutions, representing an important component of the evolving medical technology and diagnostics landscape.
XRAY's earnings report showed better-than-expected Q4 sales, leading to a 10.7% stock rally, with a 10.69% intraday gain and a 3.07% gap.
DENTSPLY SIRONA's stock is experiencing low float institutional accumulation, which can intensify pressure and amplify moves, with some analysts raising their price targets on the stock.

Generated by AI

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how dental equipment & technology stocks fared in Q2, starting with Dentsply Sirona (NASDAQ:XRAY).

4d agoYahoo Finance

Dentsply Sirona stock hits 52-week low at 9.35 USD

4d agoInvesting.com

Dentsply Sirona: The Valuation Is Low, But The Turnaround Is Not Proven Yet (NASDAQ:XRAY)

8d agoSeeking Alpha

Dentsply Sirona Inc stock hits 52-week low at 9.4 USD

12d agoInvesting.com

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now

12d agoYahoo Finance

Also Discussed

Investors talking about XRAY also mention

#	Name	Attention
1	PDCO - Patterson Companies, Inc.	——
2	Henry Schein, Inc.HSIC	0%0
3	Align Technology Inc.ALGN	0%new
4	Envista Holdings Corp.NVST	0%0
5	NVRO - Nevro Corp.	——
6	AdaptHealth CorpAHCO	0%0
7	ZIMV - ZimVie Inc.	——
8	Zimmer Biomet Holdings, Inc.ZBH	0%0
9	PRFT - Perficient, Inc.	——
10	Omnicell, Inc.OMCL	0%0

Dentsply Sirona Inc.

Healthcare
Medical Instruments & Supplies

Dentsply Sirona Inc. is a global dental products and technologies company that serves dental practices, clinics, laboratories, and distributors worldwide. The company develops, manufactures, and markets a broad portfolio that includes dental consumables, restorative materials, digital imaging systems, CAD/CAM restoration platforms, treatment centers, handpieces, hygiene systems, orthodontic and implant products, and specialty solutions for endodontics and other oral care applications. Dentsply Sirona also provides workflow-oriented technologies designed to support diagnosis, treatment planning, and chairside procedures across modern dental settings. Headquartered in Charlotte, North Carolina, Dentsply Sirona is a major supplier in the professional dental market, combining equipment, software-enabled tools, and everyday consumables to support clinical efficiency and patient care.

Website

Location

13320 Ballantyne Corporate Place

Charlotte, NC, 28277-3607

United States

Social

What share of all stock conversation is about XRAY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Feb 27

DENTSPLY SIRONA Inc. (XRAY) has seen a 10.7% rally after better-than-expected Q4 sales, with a 3.07% gap and heavy trading interest.
The company's low float has created accumulation dynamics, with institutional accumulation intensifying pressure and supply constraint against 86 GW EIA forecast tailwind demand scarcity.
Analysts maintain a bullish stance on XRAY, with Baird raising the price target from $12 to an unspecified amount, and Evercore ISI Group raising the price target from $12 to an unspecified amount.

Generated by AI

Sentiment

Of the messages about XRAY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50% -50	83.33% -3.15	86.14% -8.04
Bearish	0%	50% new	16.67% +3.15	13.86% +8.04

Bullish· Mar 1

DENTSPLY SIRONA Inc.'s (XRAY) earnings beat estimates, with a 3c beat on EPS consensus and a $44.66M beat on revenue consensus.
The company's FY19 adj. EPS guidance of $2.25-$2.40 exceeded consensus estimates of $2.17, contributing to a 15% stock price increase.
XRAY's strong earnings report led to a significant price jump, with the stock closing up 17.65% and outperforming large-cap peers.

Bearish· Apr 19

The CEO and CFO of DENTSPLY SIRONA Inc. ($XRAY) have departed within a week, raising concerns about the company's leadership.
The company has issued downside guidance, with expected EPS of $0.48-0.52 and Q1 revenue of $965 million, compared to consensus estimates of $0.67 and $1.02 billion.
Multiple analysts have downgraded their ratings on $XRAY, including Bank of America, Robert W. Baird, and William Blair, citing concerns about the company's management and earnings outlook.

Generated by AI

Topics

Of the messages about XRAY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	0%	52.82%
Analysts	—	100%	100%	7.06%
Technical Analysis	—	0%	0%	13.28%
Earnings	—	0%	0%	26.55%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0.28%

Earnings· May 10

Dentsply Sirona's Q1 earnings missed street expectations, with a non-GAAP EPS of $0.52 missing by $0.02 and revenue of $965M missing by $17.05M.
The company guided FY22 EPS below consensus and revenue below consensus, with updated guidance of $2.35-$2.55 EPS and revenue of $4.10-$4.20 billion.
Dentsply Sirona's Q1 earnings resulted in a stock price decline of 3.30% to $39.25, with the company's market value reaching $7.84B.

Analysts· Aug 8

Morgan Stanley downgraded DENTSPLY SIRONA $XRAY to "Equal Weight".
Robert W. Baird downgraded DENTSPLY SIRONA $XRAY to "Neutral".
Stifel Nicolaus cut DENTSPLY SIRONA $XRAY's price target to $46.

Announcements· Feb 28

Dentsply Sirona expects FY23 net sales of $3.85B-$3.95B, vs. $3.82B estimate, and adjusted EPS of $1.80-$2.00, vs. $1.84 estimate.
The company reported Q4 2022 results, with net sales of $1.10B and EPS of $0.55, beating estimates and guiding FY23 EPS in-line and revs above consensus.
Dentsply Sirona reported a new government contract worth $457,801.45 for its Sirona X-Ray for Dental Expansion.

Controversies· Nov 2

Dentsply Sirona completes internal investigation, but details of the investigation are not disclosed.
The investigation's outcome is not explicitly stated, leaving investors with unanswered questions.
The company's handling of the investigation has raised concerns among investors and stakeholders.

Generated by AI

Community

Of the messages about XRAY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	88.73%	62.7%
Newcomers	0%	50%	11.27%	37.3%

Regulars· Feb 28

Dentsply Sirona reported Q4 non-GAAP EPS of $0.46, beating estimates by $0.13, and revenue of $983M, beating by $43.89M.
The company guides FY23 net sales of $3.85B-$3.95B, vs. $3.82B estimate, and adjusted EPS of $1.80-$2.00, in-line with estimates.
Dentsply Sirona's FY23 organic sales growth is expected to be approximately 1%, with adjusted EBITDA margin greater than 15%, beating expectations.

Newcomers· Feb 27

DENTSPLY SIRONA (XRAY) is a global leader in dental technology and digital workflow solutions, representing an important component of the evolving medical technology and diagnostics landscape.
XRAY's earnings report showed better-than-expected Q4 sales, leading to a 10.7% stock rally, with a 10.69% intraday gain and a 3.07% gap.
DENTSPLY SIRONA's stock is experiencing low float institutional accumulation, which can intensify pressure and amplify moves, with some analysts raising their price targets on the stock.

Generated by AI

Dentsply Sirona

Social

Feb 27

Bullish· Mar 1

Bearish· Apr 19

Earnings· May 10

Analysts· Aug 8

Announcements· Feb 28

Controversies· Nov 2

Regulars· Feb 28

Newcomers· Feb 27

Dentsply Sirona's Troubles Are Nothing To Smile About (Downgrade) (NASDAQ:XRAY)

Q2 Rundown: Dentsply Sirona (NASDAQ:XRAY) Vs Other Dental Equipment & Technology Stocks

Dentsply Sirona stock hits 52-week low at 9.35 USD

Dentsply Sirona: The Valuation Is Low, But The Turnaround Is Not Proven Yet (NASDAQ:XRAY)

Dentsply Sirona Inc stock hits 52-week low at 9.4 USD

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now

Also Discussed

Dentsply Sirona Inc.

Company Information

Location

Dentsply Sirona's Troubles Are Nothing To Smile About (Downgrade) (NASDAQ:XRAY)

Q2 Rundown: Dentsply Sirona (NASDAQ:XRAY) Vs Other Dental Equipment & Technology Stocks

Dentsply Sirona stock hits 52-week low at 9.35 USD

Dentsply Sirona: The Valuation Is Low, But The Turnaround Is Not Proven Yet (NASDAQ:XRAY)

Dentsply Sirona Inc stock hits 52-week low at 9.4 USD

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now

Also Discussed

Social

Feb 27

Bullish· Mar 1

Bearish· Apr 19

Earnings· May 10

Analysts· Aug 8

Announcements· Feb 28

Controversies· Nov 2

Regulars· Feb 28

Newcomers· Feb 27